Company News in the Life Science Industry

»

Reset 

Zentiva Expands Production Capacity by Completing Acquisition of Ankleshwar Manufacturing Site

PRAGUE, June 1, 2020 /PRNewswire/ -- Zentiva Group announces the completion of its acquisition of a manufacturing site in Ankleshwar, India, from Sanofi. The finalization of the deal increases the number of wholly-owned Zentiva production sites worldwide and will enable Zentiva to serve more... Read more ››

By: PR Newswire Association LLC. - 01 Jun 2020

New Analysis Confirms That Multiple Myeloma Patients in the OCEAN Study Stay on Treatment Longer Than Previously Estimated - Results Expected H1-2021

STOCKHOLM, June 1, 2020 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announces that patients in the OCEAN study stay on treatment longer than previously estimated. As a consequence, top-line results are estimated for H1 2021 instead of previously communicated Q4 2020. Patient... Read more ››

By: PR Newswire Association LLC. - 01 Jun 2020
Related companies:  Oncopeptides AB

RDIF and ChemRar to Deliver 60,000 Courses of the First COVID-19 Drug Registered in Russia, Avifavir, to the Country's Hospitals in June

MOSCOW, June 1, 2020 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, and the ChemRar Group will deliver 60,000 courses of Avifavir to Russian hospitals in June. Avifavir is Russia's first COVID-19 drug and has shown high efficacy in... Read more ››

By: PR Newswire Association LLC. - 01 Jun 2020

IrisGuard Leads the Way in Contact-free Iris Verification Payment Services with ISO Level 1 PAD Test Compliance

MILTON KEYNES, England, June 1, 2020 /PRNewswire/ -- IrisGuard are delighted to announce that they have received their final certification and notice of compliance for Presentation Attack Detection to internationally recognised ISO 30107-3 standards from independent test house specialists, iBeta... Read more ››

By: PR Newswire Association LLC. - 01 Jun 2020

Reporter Gene Assay Market Size Worth $9.0 Billion by 2027: Grand View Research, Inc.

SAN FRANCISCO, June 1, 2020 /PRNewswire/ --The global... Read more ››

By: PR Newswire Association LLC. - 01 Jun 2020

Free COVID-19 Webinar Headlines Birth Defects Research Virtual Annual Meeting

RESTON, Va., June 1, 2020 /PRNewswire/ -- As scientists around the globe continue the race to develop a safe and effective vaccine for COVID-19, the world's leading birth defects scientists present the latest research pertaining to the infection during pregnancy. The free webinar on June 11 from... Read more ››

By: PR Newswire Association LLC. - 01 Jun 2020

Many Canadians relying on family and friends for mental health support during COVID-19

Five signs that may indicate you need additional support

Read more ››
By: PR Newswire Association LLC. - 01 Jun 2020

Aruvant Appoints Dr. Palaniappan as Chief Technology Officer

NEW YORK and BASEL, Switzerland, June 1, 2020 /PRNewswire/ -- Aruvant Sciences Inc. (Aruvant), a clinical-stage biopharmaceutical company focused on developing and commercializing transformative therapies for the treatment of severe blood disorders, today announced the appointment of V. "Palani"... Read more ››

By: PR Newswire Association LLC. - 01 Jun 2020
Related companies:  Aruvant Sciences, Inc.

Hua Medicine Selected for Inclusion in the MSCI Hong Kong Micro Cap Index

Read more ››
By: GlobenewsWire - 01 Jun 2020
Related companies:  Hua Medicine

Acacia Pharma Announces Debt for Equity Swap with Cosmo Pharmaceuticals

Read more ››
By: GlobenewsWire - 01 Jun 2020
Related companies:  Acacia Pharma

iTeos Therapeutics Appoints Ann D. Rhoads to Board of Directors

Read more ››
By: GlobenewsWire - 01 Jun 2020

Establishment of the Blue Apple New Frontier Healthcare Fund

HONG KONG, June 1, 2020 /PRNewswire/ -- New Frontier Capital Management Hong Kong has signed a collaborative MOU with Blue Apple Partners to establish the "Blue Apple New Frontier Healthcare Fund" (tentative name; the "Fund") to be jointly managed by both parties.

Read more ››
By: PR Newswire Association LLC. - 01 Jun 2020

Immutep Reports First Results from INSIGHT-004 Study

Read more ››
By: GlobenewsWire - 01 Jun 2020

Immutep Announces Improving Data from the Phase II TACTI-002 Study

Read more ››
By: GlobenewsWire - 01 Jun 2020

Innovent Biologics Announced the Results of the Phase 1b Clinical Study of TYVYT® (Sintilimab Injection) in Combination with IBI305 (Bevacizumab Biosimilar) in the Treatment of Advanced Hepatocellular Carcinoma

SUZHOU, China, May 31, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, announced... Read more ››

By: PR Newswire Association LLC. - 01 Jun 2020

Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT(R) (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type)

SUZHOU, China, June 1, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, announced... Read more ››

By: PR Newswire Association LLC. - 01 Jun 2020
Related companies:  Innovent Biologics Co., Ltd.

Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT(R) (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

SUZHOU, China, June 1, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines, jointly announced with Eli Lilly and Company (Lilly) (NYSE: LLY) the results of TYVYT(R)... Read more ››

By: PR Newswire Association LLC. - 01 Jun 2020
Related companies:  Eli Lilly and Company

Innovent Biologics Announced the Results of the Phase 1b Clinical Study of TYVYT(R) (Sintilimab Injection) in Combination with IBI305 (Bevacizumab Biosimilar) in the Treatment of Advanced Hepatocellular Carcinoma

SUZHOU, China, June 1, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, announced... Read more ››

By: PR Newswire Association LLC. - 01 Jun 2020

Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

SUZHOU, China, May 31, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines, jointly announced with Eli Lilly and Company (Lilly) (NYSE: LLY) the results of TYVYT®... Read more ››

By: PR Newswire Association LLC. - 01 Jun 2020
Related companies:  Eli Lilly and Company

Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type)

SUZHOU, China, May 31, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, announced... Read more ››

By: PR Newswire Association LLC. - 01 Jun 2020
Related companies:  Innovent Biologics Co., Ltd.
«  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23 24  25 »

Explore our database of over 50,000 companies